Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELOCITY-HNSCC Substudy-01: Domvanalimab and Zimberelimab in 1L R/M HNSCC
NCT06727565Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised trial of domvanalimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Objective Response Rate at 36 months and Progression-Free Survival at 36 months. Started Feb 2025; status: active, not recruiting.
02
Drugs
domvanalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06727565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727565.